CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: A 12-week, double-blind, placebo-controlled study

Current Alzheimer Research

Volumn 10, Issue 7, 2013, Pages 742-743

  Ross, Joel ^a   Sharma, Sanjiv ^b   Winston, Jaron ^c   Nunez, Margarita ^d   Bottini, Gabriella ^e   Franceschi, Massimo ^f   Scarpini, Elio ^g   Frigerio, Enrico ^h   Fiorentini, Francesco ^h   Fernandez, Mercedes ⁱ   Sivilia, Sandra ⁱ   Giardino, Luciana ⁱ   Calzà, Laura ⁱ   Norris, Dottie ^j   Cicirello, Helen ^j   Casula, Daniela ^k,l   Imbimbo, Bruno P ^k  

^a Memory Enhancement Center   (United States)

^b Memory Enhancement Center of New Jersey   (United States)

^c Senior Adults Specialty Research   (United States)

^d Comprehensive Clinical Research ^*  (United States)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f IRCCS MULTIMEDICA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h Accelera Srl   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j CHIESI FARMACEUTICI S P A   (Italy)

^k Chiesi Farmaceutici   (Italy)

^l NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

more..

Author keywords

Biomarkers; Microglial modulators; Mild cognitive impairment; Neuroinflammation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CD40 LIGAND; CHF 5074; GAMMA SECRETASE INHIBITOR; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD LEVEL; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CLINICAL LABORATORY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; EXECUTIVE FUNCTION; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MILD COGNITIVE IMPAIRMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NERVOUS SYSTEM INFLAMMATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SCIATICA; TAKOTSUBO CARDIOMYOPATHY; VITAL SIGN; VOMITING;

ADULT; AGED; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; COHORT STUDIES; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLURBIPROFEN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84888267995     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/13892037113149990144     Document Type: Article

References (45)

1. Mrak RZ, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26(3): 349-354 (2005).
2. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1): a006346 (2012).
3. Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel y-secretase modulator, reduces brain p-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 323(3): 822-830 (2007).
4. Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, et al. CHF5074, a novel y-secretase modulator, attenuates brain p-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 56(6): 982-993 (2009).
5. Imbimbo BP, Giardino L, Sivilia S, Giuliani A, Gusciglio M, Pietrini V, et al. CHF5074, a novel y-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 20(1): 159-173 (2010).
6. Lanzillotta A, Sarnico I, Benarese M, Branca C, Baiguera C, Hutter-Paier B, et al. The y-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci 45(1): 22-31 (2011).
7. Balducci C, Mehdawy B, Mare L, Giuliani A, Lorenzini L, Sivilia S, et al. The y-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 Mice. J Alzheimers Dis 24(4): 799-816 (2011).
8. Imbimbo BP, Frigerio E, Breda M, Fiorentini F, Fernandez M, Sivilia S, et al. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Alzheimer Dis Assoc Disord 2012 Aug 23. [Epub ahead of print].
9. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment. Ten years later. Arch Neurol 66(12): 1447-1455 (2009).
10. Imbimbo BP, Mackintosh D, Aponte T, Frigerio E, Breda M, Fernandez M, et al. Pharmacokinetics and pharmacodynamics of CHF5074, a novel y-secretase modulator, after single oral administration to healthy male subjects. 13th International Conference on Alzheimer's Disease. Honolulu, July 10-15, 2010. Alzheimer's & Dementia 2010, 6 (Supplement 1): S573 (Abstract P3-411).
11. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23(2): 312-328 (2006).
12. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65(4): 403-413 (2009).
13. Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of p-amyloid1-42 secretion. J. Med. Chem. 48(18): 5705-5720 (2005).
14. Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, et al. In vitro and in vivo profiling of CHF5022 and CHF5074 Two p-amyloid1-42 lowering agents. Pharmacol Res 55(4): 318-328 (2007).
15. Porrini V, Branca C, Lanzillotta A, Benarese M, Imbimbo BP, Pizzi M. CHF5074, in clinical development for the treatment and prevention of Alzheimer's disease, switches cultured microglia from M1 to M2 activation state. The 11th International Conference on Alzheimer's & Parkinson's Diseases. Florence, March 6-10, 2013.
16. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40-CD40L interaction after pi-amyloid stimulation. Science 286(5448): 2352-2355 (1999).
17. Calingasan NY, Erdely HA, Altar CA. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging 23(1): 31-39 (2002).
18. Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR, et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid p-peptide. Eur J Immunol 35(3): 901-910 (2005).
19. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Ap-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging 33(7):1329-1342 (2012).
20. Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5(12): 1288-1293 (2002).
21. Todd Roach J, Volmar CH, Dwivedi S, Town T, Crescentini R, Crawford F, et al. Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Res 1015(1-2): 161-168 (2004).
22. Laporte V, Ait-Ghezala G, Volmar CH, Mullan M. CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. J Neuroinflammation 3:3 (2006).
23. Desideri G, Cipollone F, Necozione S, Marini C, Lechiara MC, Taglieri G, et al. Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role. Neurobiol Aging 29(3): 348-356 (2008).
24. Ait-ghezala G, Abdullah L, Volmar CH, Paris D, Luis CA, Quadros A, et al. Diagnostic utility of APOE, soluble CD40, CD40L, and Ap1-40 levels in plasma in Alzheimer's disease. Cytokine 44(2): 283-287 (2008).
25. Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson O. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neurosci Lett 450(1): 56-59 (2009).
26. Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA, et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neuroscience 14(1): 44 (2013).
27. Town T, Nikolic V, Tan J. The microglial activation continuum: from innate to adaptive responses. J Neuroinflammation 2: 24 (2005).
28. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, et al. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 119(12): 3692-3702 (2009).
29. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 4(1): 27-36 (2010).
30. Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF, et al. Microglial activation in healthy aging. Neurobiol Aging 34(1): 128-136 (2013).
31. Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 66(1): 60-67 (2009).
32. Frigerio E, Breda M. Bioanalytical and toxicokinetic report for the quantification of CHF 5074 in brain tissues and cerebrospinal fluid for the study CHF 5074: 4 week oral toxicity study in dogs followed by a 4 week recovery period. Accelera S.r.l., Nerviano, Italy. Report 0068-2009-R. May 21, 2009.
33. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70(1): 17-24 (2008).
34. Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, et al. A randomized controlled study on effects of ibupro-fen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res 21(2): 102-110 (2009).
35. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 63(3): 287-303 (2009).
36. Ross J, Thompson PM, Doody RS, Tariot PN, Reiman EM, Lang-baum J, et al. Long-term longitudinal biomarker trials in subjects at genetic risk of developing Alzheimer's disease: the GEPARD-AD studies. J Nutr Health Aging 16(9): 799 (Abstract OC6)(2012).
37. Schor NF. What the halted phase III y-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69(2): 237-239 (2011).
38. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Rich-ter RW, et al. Safety and tolerability of the y-secretase inhibitor avagacestat in a Phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69(11): 1430-1440 (2012).
39. Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, et al. Differential effects between y-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 32(6): 2037-2050 (2012).
40. Scheltens P, Sperling R, Salloway S, Fox N. Bapineuzumab IV Phase 3 results. J Nutr Health Aging 16(9): 797 (Abstract S2) (2012).
41. Doody RS. Safety and efficacy of solaneuzumab in patients with mild to moderate Alzheimer's disease: results from Phase 3. J Nutr Health Aging 16(9): 801 (Abstract UCT1-1) (2012).
42. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634): 216-223 (2008).
43. Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77(13): 1253-1262 (2011).
44. Galasko DR, Van Dyck C, Sabbagh M, Thomas RT, Aisen PS, Kupiec J. A randomized trial of a RAGE-Ap interactions in patients with mild to moderate AD. J Nutr Health Aging 15(Suppl 1): S9 (Abstract O12) (2011).
45. Morley JE, Farr SA. Hormesis and amyloid-p protein: physiology or pathology? J Alzheimers Dis 29(3): 487-492 (2012).